들이마신 경우,호흡이 어려운 경우 환자를 신선한 공기가 있는 곳으로 옮기고 호흡하기 편한 자세로 안정을 취하게 함
P321
(…) 처치를 하시오.
P330
입을 씻어내시오.
P333+P313
피부자극성 또는 홍반이 나타나면 의학적인 조치·조언를 구하시오.
P342+P311
호흡기 증상이 나타나면 의료기관(의사)의 진찰을 받으시오.
P363
다시 사용전 오염된 의류는 세척하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
탁599 C화학적 특성, 용도, 생산
개요
Ceftaroline fosamil, also referred to as TAK-599, is a cephalosporin
antibacterial agent that was approved in the United States in October
2010 for the IV treatment of acute bacterial skin and skin structure infections
(ABSSSI) and community-acquired bacterial pneumonia (CABP).
Ceftaroline fosamil is the water-soluble, N-phosphono prodrug of ceftaroline
(T-91825), a broad-spectrum, bactericidal agent with potent activity
against methicillin-resistant Staphylococcus aureus (MRSA) strains, multidrug
resistant S. pneumonia, and common gram-negative organisms.
Ceftaroline binds to PBP2a as well as other PBPs with high
affinity and, as a result, retains potent activity. Ceftaroline exhibits activity
against most gram-positive pathogens, including β-lactam-susceptible
and -resistant S. aureus, vancomycin-resistant S. aureus, and resistant and
susceptible forms of S. pneumoniae but has weak activity against Enterococcus
sp. The gram-negative antibacterial activity of ceftaroline is limited mainly
to respiratory pathogens such as Moraxella catarrhalis and Haemophilus influenzae.
정의
ChEBI: An acetate salt obtained by reaction of ceftaroline fosamil with one equivalent of acetic acid. A prodrug for ceftaroline, used for the treatment of adults with acute bacterial skin and skin structure infections.
